Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

Bevacizumab

  • You have access
    Alternating Oxaliplatin and Irinotecan Chemotherapy Combined With Capecitabine and Bevacizumab for Microsatellite-stable Stage IV Metastatic Colon Cancer With a BRAF V600E Mutation: Two Case Reports Indicating Survival Improvement over Standard Therapy
    YAOYI ZHANG, XIAOHUI LI, SHENG LI, ZHIJIAN YANG, ROBERT M. HOFFMAN and CHEN YU
    Anticancer Research January 2025, 45 (1) 399-404; DOI: https://doi.org/10.21873/anticanres.17428
  • You have access
    Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab
    KUNIHIDE MOHRI, HIDENARI NAGAI, TAKAHISA MATSUDA, YOSHINORI IGARASHI and KOJI HIGAI
    Anticancer Research September 2024, 44 (9) 3919-3929; DOI: https://doi.org/10.21873/anticanres.17220
  • You have access
    Importance of Atezolizumab Plus Bevacizumab Combination Treatment as First-line Therapy for Immunological Changes in Patients With Unresectable Hepatocellular Carcinoma
    KOJIRO KOBAYASHI, HIDENARI NAGAI, TEPPEI MATSUI, TAKAHISA MATSUDA and KOJI HIGAI
    Anticancer Research October 2023, 43 (10) 4601-4609; DOI: https://doi.org/10.21873/anticanres.16654
  • Open Access
    Real-world Efficacy and Safety of Bevacizumab for Advanced or Recurrent Müllerian Cancer: A Single-institutional Experience
    TAKESHI FUKUDA, TAKUYA NODA, EIJIRO UCHIKURA, YUICHIRO AWAZU, REIKO TASAKA, KENJI IMAI, MAKOTO YAMAUCHI, TOMOYUKI ICHIMURA, TOMOYO YASUI and TOSHIYUKI SUMI
    Anticancer Research July 2023, 43 (7) 3097-3105; DOI: https://doi.org/10.21873/anticanres.16481
  • You have access
    Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy
    SERIKA MATSUOKA, HIRONORI FUJII, HIROTOSHI IIHARA, KOICHI OHATA, CHIEMI HIROSE, DAICHI WATANABE, SHIORI SADAKA, SHIGERU KIYAMA, AKITAKA MAKIYAMA, TAKAO TAKAHASHI, RYO KOBAYASHI, NOBUHISA MATSUHASHI and AKIO SUZUKI
    Anticancer Research May 2023, 43 (5) 2351-2357; DOI: https://doi.org/10.21873/anticanres.16400
  • Open Access
    Relationship Between Safety and Cumulative Bevacizumab Dose in Patients With Metastatic Colorectal Cancer Who Received Long-term Bevacizumab Treatment
    SATOSHI FUKUDA, YUSUKE NIISATO, MIKI TSUJI, SOMA FUKUDA, YUYA HAGIWARA, TSUBASA ONODA, HIROSUMI SUZUKI, YOSHITAKA TANGE, TAKESHI YAMADA, YOSHIYUKI YAMAMOTO and TOSHIKAZU MORIWAKI
    Anticancer Research May 2023, 43 (5) 2085-2090; DOI: https://doi.org/10.21873/anticanres.16369
  • Open Access
    Atezolizumab Retains Cellular Binding to Programmed Death Ligand 1 Following Aerosolization via Mesh Nebulizer
    GINTARAS ZALESKIS, MARTYNAS TALAIKIS, DAINIUS CHARACIEJUS, VINCAS URBONAS, PAULIUS BOSAS, ADAS DARINSKAS, LAVIJA ZIBUTYTE, LUKAS SIMKUS, ZILVINAS SURVILA, JURGITA JURSENAITE and MARGARITA ZVIRBLE
    Anticancer Research March 2023, 43 (3) 1065-1072; DOI: https://doi.org/10.21873/anticanres.16251
  • Open Access
    Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
    MARINA ABE, TADAHIRO SHOJI, YOHEI CHIBA, ERIKO TAKATORI, YOSHITAKA KAIDO, TAKAYUKI NAGASAWA, MASAHIRO KAGABU, FUMIAKI TAKAHASHI, TAKESHI AIDA and TSUKASA BABA
    Anticancer Research March 2023, 43 (3) 1265-1272; DOI: https://doi.org/10.21873/anticanres.16273
  • You have access
    Bevacizumab Plus Carboplatin Plus Nab-paclitaxel for Non-squamous Non-small Cell Lung Cancer in a Real-world Setting
    AKIHIRO TAMIYA, MOTOHIRO TAMIYA, YUJI INAGAKI, YOSHIHIKO TANIGUCHI, KEIKO NAKAO, YOSHINOBU MATSUDA, TAKAHISA KAWAMURA, KEI KUNIMASA, TAKAKO INOUE, KAZUMI NISHINO and KYOICHI OKISHIO
    Anticancer Research March 2023, 43 (3) 1325-1330; DOI: https://doi.org/10.21873/anticanres.16280
  • You have access
    Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
    YEN-HAO CHEN, YEN-YANG CHEN, JING-HOUNG WANG and CHAO-HUNG HUNG
    Anticancer Research March 2023, 43 (3) 1377-1384; DOI: https://doi.org/10.21873/anticanres.16286

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 11
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire